HUP0100012A3 - Use for macrolides for the treatment of cancer and macular degeneration - Google Patents

Use for macrolides for the treatment of cancer and macular degeneration

Info

Publication number
HUP0100012A3
HUP0100012A3 HU0100012A HUP0100012A HUP0100012A3 HU P0100012 A3 HUP0100012 A3 HU P0100012A3 HU 0100012 A HU0100012 A HU 0100012A HU P0100012 A HUP0100012 A HU P0100012A HU P0100012 A3 HUP0100012 A3 HU P0100012A3
Authority
HU
Hungary
Prior art keywords
macrolides
cancer
treatment
macular degeneration
macular
Prior art date
Application number
HU0100012A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of HUP0100012A2 publication Critical patent/HUP0100012A2/hu
Publication of HUP0100012A3 publication Critical patent/HUP0100012A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HU0100012A 1997-10-31 1998-10-30 Use for macrolides for the treatment of cancer and macular degeneration HUP0100012A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96147397A 1997-10-31 1997-10-31
PCT/US1998/023043 WO1999022722A2 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration

Publications (2)

Publication Number Publication Date
HUP0100012A2 HUP0100012A2 (hu) 2001-05-28
HUP0100012A3 true HUP0100012A3 (en) 2003-07-28

Family

ID=25504514

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100012A HUP0100012A3 (en) 1997-10-31 1998-10-30 Use for macrolides for the treatment of cancer and macular degeneration

Country Status (17)

Country Link
EP (1) EP1027060A2 (sk)
JP (1) JP2001521891A (sk)
KR (1) KR20010031577A (sk)
CN (1) CN1278178A (sk)
AR (1) AR043071A1 (sk)
AU (1) AU1206799A (sk)
BG (1) BG104436A (sk)
BR (1) BR9813318A (sk)
CA (1) CA2307850A1 (sk)
HU (1) HUP0100012A3 (sk)
IL (1) IL135518A0 (sk)
NO (1) NO20002189L (sk)
PL (1) PL340604A1 (sk)
SK (1) SK6172000A3 (sk)
TR (1) TR200001147T2 (sk)
WO (1) WO1999022722A2 (sk)
ZA (1) ZA989885B (sk)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079520A1 (en) 2000-04-13 2001-10-25 Biotica Technology Limited Hybrid glycosylated products and their production and use
PT1539157E (pt) 2002-09-18 2013-10-04 Univ Pennsylvania Rapamicina para utilização na inibição ou prevenção de neovascularização coroidal
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
CA2520377A1 (en) 2003-03-28 2004-10-14 Cornell Research Foundation, Inc. Migrastatin analog compositions and uses thereof
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
CN108101948A (zh) * 2004-02-27 2018-06-01 瑞伯-X医药品有限公司 大环化合物以及其制作和使用方法
US8202843B2 (en) * 2004-02-27 2012-06-19 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
EP1805161B1 (en) 2004-09-23 2014-05-07 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
ES2564194T3 (es) 2005-02-09 2016-03-18 Santen Pharmaceutical Co., Ltd. Formulaciones líquidas para el tratamiento de enfermedades o dolencias
PL1904056T3 (pl) 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
WO2007025089A2 (en) 2005-08-24 2007-03-01 Rib-X Pharmaceutical, Inc. Triazole compounds and methods of making and using the same
ES2638427T3 (es) 2005-08-24 2017-10-20 Melinta Therapeutics, Inc. Compuestos de triazol y procedimientos de preparación y uso del mismo
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
CN106317146B (zh) * 2015-06-18 2019-06-21 沈阳药科大学 双环克拉霉素衍生物及其作为肿瘤细胞增值抑制剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6461090A (en) * 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Also Published As

Publication number Publication date
IL135518A0 (en) 2001-05-20
SK6172000A3 (en) 2001-03-12
PL340604A1 (en) 2001-02-12
NO20002189D0 (no) 2000-04-27
AR043071A1 (es) 2005-07-20
CN1278178A (zh) 2000-12-27
WO1999022722A2 (en) 1999-05-14
BR9813318A (pt) 2000-08-22
EP1027060A2 (en) 2000-08-16
HUP0100012A2 (hu) 2001-05-28
TR200001147T2 (tr) 2000-08-21
NO20002189L (no) 2000-06-28
KR20010031577A (ko) 2001-04-16
ZA989885B (en) 1999-05-05
BG104436A (en) 2000-12-29
AU1206799A (en) 1999-05-24
JP2001521891A (ja) 2001-11-13
CA2307850A1 (en) 1999-05-14
WO1999022722A3 (en) 1999-08-05

Similar Documents

Publication Publication Date Title
HUP0104081A3 (en) Device for the treatment of macular degeneration
IL135518A0 (en) Use of macrolides for the treatment of cancer and macular degeneration
ZA979096B (en) Viral and cancer treatment
ZA957483B (en) Compounds and methods for the treatment of cancer
AU2212299A (en) Compositions and methods for the treatment of tumor
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
HUP0102473A3 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
AU2476200A (en) Ribozyme therapy for the treatment and/or prevention of restenosis
IL141426A0 (en) Compositions and methods for the treatment of tumor
AU8068198A (en) Methods for treating human cancers
IL143212A0 (en) Compositions and methods for the treatment of tumor
IL142778A0 (en) Therapeutic product and its use
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
GB9819999D0 (en) Treatment of cancer
ZA984650B (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
EP1023076A4 (en) USE OF THE P-TEN TUMOR SUPPRESSOR GENE IN THE DIAGNOSIS AND TREATMENT OF CANCER
GB9828564D0 (en) Materials and methods for the treatment and diagnosis of cancer
AU6288698A (en) Apparatus for stimulating the human body
AU6404698A (en) Treatment methods for obtaining therapeutic products and resulting products
AU4406899A (en) Progesterone treatment of cancer
AU3205295A (en) Antisense oligonucleotides and methods for the treatment of schistosomiasis
ZA988293B (en) Compositions and methods for the treatment of tumor.
GB9703517D0 (en) Steroid treatment
AUPO955497A0 (en) Treatment of cancer